Skip to main content
Equibles
MREO logo

MREO · Mereo BioPharma Group plc · Metrics

Track MREO — free

Use MREO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MREO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.30 +0.01 (+2.24%)
Rebalance outlook locked
Market Cap
$47.12M
Shares
159.69M
Volume · Oct 21 329.27K Avg daily vol (3M) 3.99M

MREO metrics

75 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.29
Market cap
$47.12M

Price action

20 metrics
Price change (1W)
-7.8%
Price change (30D)
+1.7%
Price change (3M)
-3.6%
Price change (6M)
-8.9%
Price change (YTD)
-29.2%
Price change (1Y)
-86.8%
Trailing year
Price change (5Y)
-86.3%
52-week high
$2.31
52-week low
$0.24
Change from 52-week high
-87.2%
Change from 52-week low
+24.5%
Annualized volatility
132.2%
Annualized volatility (3M)
84.2%
Beta
1.3
RSI (14D)
41.7
Price vs SMA 50
-4.3%
Price vs SMA 200
-13.8%
Avg volume (3M)
4.00M
Relative volume
0.1
Average dollar volume
$1.23M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
159.69M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.7
reciprocal yield 59.4%
FCF yield
-52.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-58.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2,276.3×
reciprocal yield 0.0%
EV / revenue historical average (5Y)
2,276.3×
reciprocal yield 0.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-11

Profitability

9 metrics
Gross margin
—
Operating margin
-8,021.4%
Trailing 12 months
Net margin
-8,375.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$34.20M
Net income (TTM)
−$28.10M
Trailing 12 months
Diluted EPS (TTM)
$-0.15
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.21
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.18
Operating cash flow per diluted share (TTM)
$-0.16
Free cash flow per diluted share (TTM)
$-0.16
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.09
Stock compensation per diluted share (TTM)
$0.04
Book value per share
$0.41

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-98.1%
Return on assets
-80.9%
Debt / equity
0.0
Current ratio
5.9
EBITDA (TTM)
—
Free cash flow (TTM)
−$25.35M
Quick ratio
5.9
Interest coverage
-393.1
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$30.12M
Latest balance sheet
Cash & equivalents
$30.12M
Total assets
$34.71M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$25.35M
Capital expenditures (TTM)
$0
R&D (TTM)
$15.02M
SG&A (TTM)
—
Stock compensation (TTM)
$6.18M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
60
13F filer change QoQ
-4
Institutional ownership
35.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
5.7%
Private-fund adviser ownership
5.5%
Active holders' share change QoQ
-24.8%
Holder tenure
15.0
Price vs estimated holder cost
-78.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.4%

Short interest

3 metrics
Short interest
1.7%
Latest settlement · 1.3 days to cover
Days to cover
1.3d
Short-squeeze score
42 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1719714 CUSIP 589492107 13F (30d) 3 filings 3 filers Visit website Investor relations